Claim 01 of 06
Death becomes optional.
Progress is measured by the rate at which frontier life expectancy is rising. That rate has moved from 0.13 to 0.17 years per calendar year since 2020, against a completion threshold of 1.00.
Primary measure
Basis of the progress score
The single objective measure assigned to this claim, tracked from the 2020 baseline to the current value. This measure alone determines the progress percentage.
Longevity Escape Velocity Ratio
Years of life expectancy added per year elapsed, measured at the frontier: the best-performing large high-income country on a five-year rolling basis. At a ratio of 1.00, life expectancy rises by a full year for each year that passes, and aging ceases to impose a fixed lifespan.
Supporting measures
Related indicators
Reported alongside the primary measure to show whether it is consistent with the wider evidence. These do not enter the progress score. Bars show relative movement only.
Recent developments
Events since 2025
Developments relevant to this claim, and their effect on the primary measure where there is one.
Completion estimate
Basis for 2052
Starting point, adjustments applied, and the resulting estimate.
The Metaculus community forecast for the date a country first reaches longevity escape velocity has a median of June 2053, based on 640 predictions from 143 forecasters.
The primary measure has changed little since the baseline. Frontier gains declined during 2020 to 2022, recovered through 2024, and now stand at approximately 0.17 years per calendar year against a completion threshold of 1.00.
One structural development occurred in 2026. The first partial epigenetic reprogramming therapy was administered to a human under regulatory clearance. This does not appear in the primary measure and is unlikely to for a decade or more, but it establishes a precedent that did not previously exist.
Computational methods are reducing the time required for target identification and molecule design. They do not reduce the time required for clinical trials. Aging trials are unusually long because no surrogate endpoint is currently accepted by regulators, so the binding constraint is trial duration rather than discovery throughput.
The estimate used here is 2052, one year earlier than the Metaculus median, reflecting the reprogramming milestone. The plausible range extends from approximately 2041 to beyond 2080.
Assessment
Arguments for and against
The strongest available case on each side, stated without weighting.
Reasons to expect completion
- Partial reprogramming reverses epigenetic age in animals.Yamanaka factor protocols reset epigenetic age markers in mice, and partial protocols have restored visual function in aged non-human primates. The mechanism has been demonstrated repeatedly across laboratories.
- Sustained long-horizon capital has entered the field.Altos Labs, Retro Biosciences, NewLimit, and Calico are funded at billion-dollar scale. NewLimit raised $435 million in 2026 with participation from an established pharmaceutical company.
- Aging research has an unusually large target space.This is the class of problem where computational discovery contributes most. 117 AI-enabled therapeutic assets are already in human trials across all indications.
- Aging is upstream of most disease burden.An effective intervention would reduce incidence across cancer, cardiovascular disease, and neurodegeneration simultaneously, which raises expected return relative to single-disease programmes.
- Approval in one jurisdiction would likely propagate.Longevity therapies face comparatively low political resistance, and cross-border access to approved treatments is already established practice.
Reasons to expect failure
- The primary measure has not moved materially.Six years past the baseline the frontier gain rate is 0.17 against a threshold of 1.00. No intervention has yet produced a measurable change in this figure.
- Maximum verified lifespan is unchanged since 1997.The record of 122.45 years has stood for 29 years without being approached, which would be the earliest visible signal of a change in the mortality curve at the top.
- Animal results have historically failed to transfer.Numerous interventions have extended murine lifespan by 20 to 40 percent without producing measurable effects in humans.
- No regulatory pathway exists for aging as an indication.Therapies must be developed against specific disease endpoints, which constrains trial design and lengthens development timelines.
- Reprogramming carries a known oncogenic risk.Complete dedifferentiation produces teratomas. The therapeutic window for partial reprogramming has not been characterised across tissues or across patient populations.
- The claim extends beyond aging.Complete control of biological aging would leave accident, violence, and infectious disease as causes of death. No current programme addresses these.
Scenarios
Most likely paths
Two sequences: the most probable route to completion and the most probable route to failure. These are structured projections, not forecasts, and neither is assigned a probability.
Most likely path to completion
The most probable sequence begins with narrow approvals rather than with a general therapy.
A partial reprogramming therapy is approved for a single localised indication, most likely ophthalmic, where dosing can be confined to one tissue and the effect observed directly. The current Life Biosciences Phase 1 targets exactly this profile. A first approval in this class would fall in the late 2020s or early 2030s.
Approved use in one tissue generates the first human data on epigenetic age reversal. Additional indications follow tissue by tissue through the 2030s: liver, thymus, haematopoietic system. Each is approved against a disease endpoint and each incidentally rejuvenates an organ system.
By the early 2040s a treated population in its seventies carries immune function comparable to an untreated population in its forties. Incidence of cancer and mortality from infection decline in that cohort. The frontier gain rate rises from 0.17 toward 0.4 and then 0.6.
Around 2050 the ratio crosses 1.00 in a single high-income country with an early regulatory framework. Remaining life expectancy at age 60 begins to increase by more than one year for each year of elapsed time.
Global diffusion follows over the subsequent two decades, constrained by manufacturing capacity and cost rather than by science.
Most likely path to failure
The most probable failure is partial success that plateaus.
Partial reprogramming proves to have a narrow and tissue-specific therapeutic window. Sub-threshold dosing produces no measurable rejuvenation and supra-threshold dosing produces tumours. Characterising that window for each tissue absorbs fifteen years and a large share of the field's capital, and yields approved therapies in a small number of accessible tissues only.
Discovery capacity continues to increase while clinical capacity does not. Candidate volume exceeds available trial slots by two to three orders of magnitude. The binding constraint becomes clinical throughput, which is not responsive to computational improvement.
Healthspan improves substantially without a corresponding change in maximum lifespan. Morbidity compresses toward the end of life. Populations remain functional into their nineties and then die on approximately the historical schedule.
The frontier gain rate plateaus near 0.3. Maximum verified lifespan remains near 120 years. Life expectancy at birth in high-income countries converges toward the high eighties and stabilises.
The other claims
Open another claim page
Each claim carries its own colour, applied as the background of its page.
